Enrollment on track in Ph 2 part of PYNNACLE trial of rezatapopt monotherapy in TP53 Y220C & KRAS WT advanced solid tumor patients August 22, 2024
Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from Ph 2 SPARTA Trial Announced August 22, 2024
FDA granted Fast Track designation to Deltacel™ (KB-GDT-01) Gamma Delta T-cell (GDT) therapy August 22, 2024
Initial Data from Ph 1 Clinical Trial of EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 announced August 13, 2024
FDA grants “Study May Proceed” letter for the Ph 1/2 study of Silmitasertib (CX-4945) + chemo in children and young adults with R/R solid tumors August 13, 2024
IDEAYA Biosciences Announces Option and License Agreement for B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen August 7, 2024
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510 and IMM27M August 7, 2024
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline July 23, 2024
Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors July 23, 2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for novel ADC July 17, 2024
IND Submission to US FDA for Ph 1/2 study of Silmitasertib (CX-4945) in children and young adults with R/R solid tumors July 17, 2024
Development of Early-Stage Bispecific T-Cell Engager AMG 794 for Solid Tumors discontinued July 17, 2024
Safety Approval Announced for the First Dose Cohort in Ph 1a/b Clinical Trial of PMC-309 in Patients with Advanced or Metastatic Solid Tumors July 17, 2024
US FDA grants IND Clearance to Conduct Ph 1/2 Study of JCXH-211 IV as Monotherapy and with Checkpoint Inhibitor in Patients with Advanced Solid Tumors July 17, 2024
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 July 9, 2024
Initial Safety and Efficacy Data from Ph 1 Trial of WTX-330 in Patients with Advanced or Metastatic Solid Tumors or NHL announced July 1, 2024
